https://scholars.lib.ntu.edu.tw/handle/123456789/494627
標題: | Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer | 作者: | Ch'ang H.-J. Wang C.-C. ANN-LII CHENG CHIUN HSU YEN-SHEN LU MING-CHU CHANG Lin J.-T. HSIU-PO WANG Shiah H.-S. Liu T.-W. Chang J.-Y. Whang-Peng J. Chen L.-T. |
公開日期: | 2006 | 出版社: | Blackwell Publishing | 卷: | 21 | 期: | 5 | 起(迄)頁: | 874-879 | 來源出版物: | Journal of Gastroenterology and Hepatology (Australia) | 摘要: | Objectives: To evaluate the feasibility and maximal tolerated dose (MTD) of oxaliplatin of a triplet regimen consisting of gemcitabine, oxaliplatin and infusional fluorouracil (5-FU)/leucovorin (LV) (GOFL) for advanced pancreatic cancer. Patients and Methods: Patients with histologically proven metastatic or unresectable, locally advanced pancreatic adenocarcinoma were eligible to take part in the study. The treatment consisted of fixed-rate infusion (10 mg/m 2/minute) of 800 mg/m2 gemcitabine followed by 2-h infusion of oxaliplatin and then 48-h infusion of 5-FU/LV day 1 and day 15 every 4 weeks. The oxaliplatin would be evaluated at three dose levels, 65, 75 and 85 mg/m2. Results: A total of 15 patients were enrolled at three dose levels. Dose-limiting toxicity of neutropenic fever and grade 4 thrombocytopenia occurred in one of each six patients at oxaliplatin dose level of 65 mg/m 2 and 85 mg/m2, respectively. The MTD of oxaliplatin for this combination was 85 mg/m2. After a median four cycles of treatment, grade 3/4 neutropenia occurred in 46.7% of patients and thrombocytopenia in 13.3%. Non-hematological toxicities were generally of grade 1/2. Objective tumor response was observed in five patients (33.3%, 95% confidence interval, 6.3-60.4%). Conclusion: Biweekly GOFL is a feasible regimen for advanced pancreatic cancer. For further phase II studies, the recommended dose of oxaliplatin is 85 mg/m2. ? 2005 Blackwell Publishing Asia Pty Ltd. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-33646900006&doi=10.1111%2fj.1440-1746.2005.04022.x&partnerID=40&md5=f34c3019e0e94c1397b0cc7e7013b50d https://scholars.lib.ntu.edu.tw/handle/123456789/494627 |
ISSN: | 0815-9319 | DOI: | 10.1111/j.1440-1746.2005.04022.x | SDG/關鍵字: | corticosteroid; fluorouracil; folinic acid; gemcitabine; oxalip; oxaliplatin; serotonin 3 antagonist; adult; advanced cancer; aged; alopecia; anemia; article; blood toxicity; cancer combination chemotherapy; clinical article; clinical trial; confidence interval; controlled clinical trial; controlled study; diarrhea; dose calculation; dose response; drug efficacy; drug infusion; fatigue; febrile neutropenia; female; histopathology; human; human cell; leukopenia; male; maximum tolerated dose; metastasis; nausea; neuropathy; neutropenia; pancreas adenocarcinoma; pancreas cancer; phase 1 clinical trial; priority journal; stomatitis; thrombocytopenia; treatment outcome; vomiting |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。